Revenio Group Oyj · OMXHEX:REG1V
Revenio Group Oyj — Q1 2025 Earnings Presentation
18 slides from Revenio Group Oyj's earnings presentation, Apr 29, 2025
Slide 1: Q1/2025 Interim report
Q1/2025 INTERIM REPORT Q1/2025 Interim report 1 29.4.2025 Revenio
Slide 2: Disclaimer
Q1/2025 INTERIM REPORT Disclaimer This presentation does not constitute an invitation to underwrite, subscribe for, or otherwise acquire or dispose of any Revenio Group Corporation’s shares. Group's past performance is no guide to future performance, and persons needing advice should consult an inde
Slide 3: Today's presenters
Q1/2025 INTERIM REPORT Today’s presenters Jouni Robin Toijala Pulkkinen CEO CFO 3 29.4.2025 Revenio
Slide 4: Agenda
Q1/2025 INTERIM REPORT Agenda 1. Highlights of Q1/2025 2. Financials of Q1/2025 3. Shareholders and financial guidance for 2025 4. Q&A 4 29.4.2025 Revenio
Slide 5: Strong start for 2025
Q1/2025 INTERIM REPORT Strong start for 2025 • The first quarter of 2025 was very strong for us, and we reached our all-time high sales and Net sales EBIT profitability for Q1 • Imaging and tonometer product lines achieved 26.1 6.6 growth in all regions MEUR (+10.5%) MEUR (+28.6%) • Sales grew in As
Slide 6: Business highlights Q1/2025
Q1/2025 INTERIM REPORT Business highlights Q1/2025 Tonometers Fundus imaging Microperimeters Software solutions Tonometer sales were Imaging sales reached The FDA granted a The number of iCare strong. strong sales growth marketing authorization for ILLUME-based screening especially for the iCare the
Slide 7: The US tariffs
Q1/2025 INTERIM REPORT The US tariffs The macroeconomic and geopolitical outlook includes uncertainties that may be reflected in our business. We are one of the most resilient companies in the market, and our position is very strong. • Our industry is defensive and backed up by macrotrends • We see
Slide 8: The US tariffs
Q1/2025 INTERIM REPORT The US tariffs We are well prepared for the U.S. tariff impact with different alternative measures: • Inventory levels already increased during Q1 • Import tariffs expected earnings impact during Q2–Q4/2025 is approximately EUR 0.8–1.4 million without price increases • Price i
Slide 9: Financials Q1/2025
Q1/2025 INTERIM REPORT Financials Q1/2025 9 29.4.2025 Revenio
Slide 10: Key figures Q1/2025
Q1/2025 INTERIM REPORT Key figures Q1/2025 MEUR 1-3/ 1-3/ Change 2025 2024 -% • Great start for the year in terms of revenue and Net sales 26.1 23.6 10.5 profitability Gross margin 19.0 16.6 14.1 Gross margin, % 72.6 70.3 2.3 • Our foreign exchange rate EBITDA adjusted sales increased by 7.7 6.2 24.
Slide 11: Strong net sales growth
Q1/2025 INTERIM REPORT Strong net sales growth Net sales (EUR million) 35 30,5 30 28,3 29,1 • Our imaging and tonometer 25,4 26,1 product lines achieved growth 24,4 24,1 25 23,2 22,3 22,0 23,6 23,9 in all regions 20 20,2 • Net sales totaled EUR 26.1 (23.6) million, up by 10.5% 15 • The currency-adju
Slide 12: Operating profit at a record level
Q1/2025 INTERIM REPORT Operating profit at a record level • Operating profit was EUR 6.6 (5.1) million, or 25.4% of net sales, up by 28.6% Adjusted operating profit EUR million and % (EBIT) 10 9,5 35 • There were no significant 9,3 9,3 extraordinary items or clinical 9 30 trial costs that would have
Slide 13: Good cash generation
Q1/2025 INTERIM REPORT Good cash generation Cash flow from operations (EUR million) 14 11,7 12 • We had improvements in the 9,8 accounts receivable and 10 inventory side of working 8 capital 7,1 6,5 5,6 • Our variable pay programs for 6 4,6 5,2 4,6 4,7 2024 were paid out during 4 Q1/25. In 2024 our
Slide 14: Unleveraged balance sheet continues to get stronger
Q1/2025 INTERIM REPORT Unleveraged balance sheet continues to get stronger Equity ratio and net gearing (%) 90 10 80,2 80 • Equity ratio above 80% for the 72,2 72,7 74,5 74,7 76,3 76,2 71,1 first time since the acquisition 70 67,4 66,2 67,4 66,8 5 64 of Centervue in 2019 60 • Our interest-bearing de
Slide 15: Shareholders on March 31, 2025
Q1/2025 INTERIM REPORT Shareholders on March 31, 2025* No. of shares % Verified Ownership 1. William Demant Invest A/S 5,589,625 20.95% 2025-03-31 2. SEB Funds 1,161,227 4.35% 2025-02-28 3. Vanguard 900,220 3.37% 2025-03-31 4. Ilmarinen Mutual Pension 801,986 3.01% 2025-03-27 Insurance Company 5. Sw
Slide 16: Financial guidance for 2025
Q1/2025 INTERIM REPORT Financial guidance for 2025 Revenio Group’s exchange rate-adjusted net sales are estimated to grow 6-15 percent from the previous year and profitability, excluding non-recurring items, is estimated to remain at a good level. 16 29.4.2025 Revenio
Slide 17: Q&A
Q1/2025 INTERIM REPORT Q&A 17 29.4.2025 Revenio
Slide 18: REVENIO
REVENIO